ACE Inhibitors News and Research

RSS

ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.

Radboudumc researchers find essential mechanism in the disease process of COVID-19

Researchers at the Radboud University Medical Center seem to have found an essential mechanism in the disease process of COVID-19, which has so far been overlooked.

29 Apr 2020

ACE inhibitors appear to be safe and beneficial for COVID-19, say researchers

Researchers in India have conducted a meta-analysis investigating the effects of using angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on outcomes among patients with COVID-19.

29 Apr 2020

Study shows why people with certain heart diseases may be more susceptible to COVID-19

People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown.

28 Apr 2020

RAS inhibitors and COVID-19 severity in hypertensive patients

A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.

23 Apr 2020

Meis1 protein plays key role in stopping cell division in the heart

UT Southwestern Medical Center scientists have discovered a protein that works with others during development to put the brakes on cell division in the heart, they report today in Nature.

23 Apr 2020

Research offers clues to how SARS-CoV-2 gets into respiratory tissue and exploits our defenses

What makes SARS-CoV-2, the virus behind COVID-19, such a threat? A new study, led by Jose Ordovas-Montanes, Ph.D. at Boston Children's Hospital and Alex K. Shalek, Ph.D. at MIT, pinpoints the likely cell types the virus infects.

22 Apr 2020

Role of ACE/ARB inhibitors in the treatment of COVID-19

A new opinion piece published in the journal Circulation Research in April 2020 defends the use of antihypertensive drugs called ACE inhibitors and ARBs in patients with pandemic viral pneumonia called COVID-19.

20 Apr 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020

Trial to evaluate how blood pressure medications affect outcomes among COVID-19 patients

A new trial led by the Perelman School of Medicine at the University of Pennsylvania will evaluate whether the use of medications to treat high blood pressure affect outcomes among patients who are prescribed the medication and hospitalized with COVID-19.

16 Apr 2020

Hypertensive patients on ACE inhibitors and angiotensin receptor blockers may have improved COVID-19 prognosis

Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.

9 Apr 2020

COVID-19 adversely impacts patients with cardiovascular disease and metabolic disorders

COVID-19 has a significant impact on patients with pre-existing conditions, many of which fall under the cardiovascular and metabolic disorder category.

3 Apr 2020

Antihypertensive drugs may protect against COVID-19 in heart patients

Common drugs used in high blood pressure, heart failure, and diabetic patients with kidney damage, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), could be protective in patients with COVID-19.

31 Mar 2020

Higher serum EPA levels from prescription fish oil associated with lower cardiovascular events

Higher levels of the omega-3 fatty acid eicosapentaenoic acid (EPA) found in the blood—and not a decrease in triglyceride levels as originally thought—appear to explain the striking reductions in cardiovascular events and deaths seen among people taking 4 grams daily of the prescription fish oil, icosapent ethyl, according to findings from a REDUCE-IT substudy presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology

30 Mar 2020

COVID-19 and its effects on the cardiovascular system

Researcher have reviewed the evidence showing the effects of the SARS-CoV-2 or novel coronavirus infection (COVID-19) on the cardiovascular system. Their study titled, “Potential Effects of Coronaviruses on the Cardiovascular System: A Review,” was published in the latest issue of JAMA Cardiology.

29 Mar 2020

Heart and kidney patients should keep taking their medicines during COVID-19 pandemic

As the COVID-19 pandemic unfolds, inaccurate medical information has flooded social media and other channels.

27 Mar 2020

What happens when COVID-19 and cardiovascular diseases mix?

The world has been brought to a stand-still by the COVID-19 pandemic that has affected 197 countries, areas and territories, infected 467,594, and killed 21,181 individuals as of today. COVID-19 disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA virus, contagious in humans.

25 Mar 2020

Patients treated with ACEIs and ARBs may be at increased risk of severe COVID-19

James Diaz, MD, MHA, MPH & TM, Dr PH, Professor and Head of Environmental Health Sciences at LSU Health New Orleans School of Public Health, has proposed a possible explanation for the severe lung complications being seen in some people diagnosed with COVID-19.

23 Mar 2020

Switching what heart cells consume could help them regenerate

Switching what the powerhouses of heart cells consume for energy could help the heart regenerate when cells die, a new study led by UT Southwestern researchers suggests.

23 Feb 2020

Guideline-recommended diuretic linked to more side effects than similar antihypertensive drug

Chlorthalidone, the guideline-recommended diuretic for lowering blood pressure, causes more serious side effects than hydrochlorothiazide, a similarly effective diuretic, according to a new study led by researchers at Columbia University Irving Medical Center.

17 Feb 2020

Cancer patients receiving common heart drugs have less heart damage from cancer therapy

Cancer patients receiving common heart drugs have less heart damage from cancer therapy, according to research presented today at EuroEcho 2019, a scientific congress of the European Society of Cardiology.

4 Dec 2019